Given this, our current finding that flutamide can restore the reduced expression of miR-449a and miR-449b-5p in HR tissues, thereby suppressing CSF1R, provides a mechanistic insight into how flutamide may potentially mitigate the risk of ovarian cancer initiation. The gene discussed is CSF1R; the disease is ovarian carcinoma.